In this episode of the Crux of Cardio, host Jordan Burgin is joined by Martin Herman, co-founder and CEO of Powerful Medical the AI-powered cardiac diagnostics company behind PM Cardio.

Martin shares how a software engineering background, a medical student brother, and a search for a truly pioneering problem led him to build an AI platform that can now diagnose 46 cardiovascular conditions from a single 12-lead ECG with over 120,000 doctors already using it in clinical practice.

They cover the journey from early scepticism to clinical proof, the brutal reality of MedTech fundraising, and what FDA breakthrough designation means for Powerful Medical's imminent US commercial launch.

Key Topics:

• How Powerful Medical identified the ECG as cardiology's biggest unsolved problem

• Building AI that outperforms experienced cardiologists on the hardest cases

• The clinical and commercial case for PM Cardio in US heart attack centres

• FDA breakthrough designation and the road to US approval this summer

• Raising €46M in non-dilutive EU grant funding and what comes next

• Winning MedTech Innovator and what it means for partnerships and validation

Related Insights:

• Why starting with the biggest clinical sceptics is actually a growth strategy

• How 64 American physician-investors validated the product with $3.5M in funding

• The difference between pre- and post-ChatGPT AI fundraising environments

• Why young founders have a structural advantage in MedTech and how to use it

Core Challenges:

• Beyond the cardiologist, almost no clinician can reliably read an ECG creating a critical diagnostic gap at the first point of patient contact that PM Cardio is designed to close.

• US hospitals chasing heart attack accreditation KPIs are generating false positive rates as high as 70–80%, costing up to $15,000 per unnecessary cath lab activation. PM Cardio reduces false positives by ~90% while maintaining diagnostic sensitivity.

• Regulatory fragmentation across 27 EU healthcare markets and the complexity of US FDA approval has been the single biggest bottleneck to commercial scale, despite overwhelming clinical evidence.

Tune in now to hear how Martin Herman turned a software engineering background and a medical student brother into a platform already saving thousands of lives and why the biggest breakthrough may still be ahead.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠